DNA barcoding and gene expression recording reveal the presence of cancer cells with unique properties during tumor progression.
Cancer stem cell
DNA barcode
Gene expression recording
NANOG
POU5F1
stgRNA
Journal
Cellular and molecular life sciences : CMLS
ISSN: 1420-9071
Titre abrégé: Cell Mol Life Sci
Pays: Switzerland
ID NLM: 9705402
Informations de publication
Date de publication:
23 Dec 2022
23 Dec 2022
Historique:
received:
22
08
2022
accepted:
19
11
2022
revised:
02
11
2022
entrez:
23
12
2022
pubmed:
24
12
2022
medline:
28
12
2022
Statut:
epublish
Résumé
Tumors comprise diverse cancer cell populations with specific capabilities for adaptation to the tumor microenvironment, resistance to anticancer treatments, and metastatic dissemination. However, whether these populations are pre-existing in cancer cells or stochastically appear during tumor growth remains unclear. Here, we show the heterogeneous behaviors of cancer cells regarding response to anticancer drug treatments, formation of lung metastases, and expression of transcription factors related to cancer stem-like cells using a DNA barcoding and gene expression recording system. B16F10 cells maintained clonal diversity after treatment with HVJ-E, a UV-irradiated Sendai virus, and the anticancer drug dacarbazine. PBS treatment of the primary tumor and intravenous injection of B16F10 cells resulted in metastases formed from clones of multiple cell lineages. Conversely, BL6 and 4T1 cells developed spontaneous lung metastases by a small number of clones. Notably, an identical clone of 4T1 cells developed lung metastases in different mice, suggesting the existence of cells with high metastatic potential. Cas9-based transcription recording analysis in a human prostate cancer cell line revealed that specific cells express POU5F1 in response to an anticancer drug and sphere formation. Our findings provide insights into the diversity of cancer cells during tumor progression.
Identifiants
pubmed: 36564568
doi: 10.1007/s00018-022-04640-4
pii: 10.1007/s00018-022-04640-4
pmc: PMC9789022
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
17Subventions
Organisme : AMED
ID : 18 cm0106341h0001
Organisme : JSPS
ID : JP21K19408
Organisme : JSPS
ID : JP21H05158
Organisme : JSPS
ID : JP21H05160
Informations de copyright
© 2022. The Author(s).
Références
Batlle E, Clevers H (2017) Cancer stem cells revisited. Nat Med 23:1124–1134. https://doi.org/10.1038/nm.4409
doi: 10.1038/nm.4409
Bhang HC, Ruddy DA, Krishnamurthy Radhakrishna V, Caushi JX, Zhao R, Hims MM, Singh AP, Kao I, Rakiec D, Shaw P, Balak M, Raza A, Ackley E, Keen N, Schlabach MR, Palmer M, Leary RJ, Chiang DY, Sellers WR, Michor F, Cooke VG, Korn JM, Stegmeier F (2015) Studying clonal dynamics in response to cancer therapy using high-complexity barcoding. Nat Med 21:440–448. https://doi.org/10.1038/nm.3841
doi: 10.1038/nm.3841
Birkbak NJ, McGranahan N (2020) Cancer genome evolutionary trajectories in metastasis. Cancer Cell 37:8–19. https://doi.org/10.1016/j.ccell.2019.12.004
doi: 10.1016/j.ccell.2019.12.004
Bystrykh LV, Belderbos ME (2016) Clonal analysis of cells with cellular barcoding: when numbers and sizes matter. In: Turksen K (ed) Stem cell heterogeneity: methods and protocols, methods in molecular biology. Springer, New York, pp 57–89. https://doi.org/10.1007/7651_2016_343
doi: 10.1007/7651_2016_343
Filipponi D, Emelyanov A, Muller J, Molina C, Nichols J, Bulavin DV (2019) DNA damage signaling-induced cancer cell reprogramming as a driver of tumor relapse. Mol Cell 74:651-663.e8. https://doi.org/10.1016/j.molcel.2019.03.002
doi: 10.1016/j.molcel.2019.03.002
Flavahan WA, Gaskell E, Bernstein BE (2017) Epigenetic plasticity and the hallmarks of cancer. Science 357:eaal2380. https://doi.org/10.1126/science.aal2380
doi: 10.1126/science.aal2380
Gerstung M, Jolly C, Leshchiner I, Dentro SC, Gonzalez S, Rosebrock D, Mitchell TJ, Rubanova Y, Anur P, Yu K, Tarabichi M, Deshwar A, Wintersinger J, Kleinheinz K, Vázquez-García I, Haase K, Jerman L, Sengupta S, Macintyre G, Malikic S, Donmez N, Livitz DG, Cmero M, Demeulemeester J, Schumacher S, Fan Y, Yao X, Lee J, Schlesner M, Boutros PC, Bowtell DD, Zhu H, Getz G, Imielinski M, Beroukhim R, Sahinalp SC, Ji Y, Peifer M, Markowetz F, Mustonen V, Yuan K, Wang W, Morris QD, Spellman PT, Wedge DC, Van Loo P (2020) The evolutionary history of 2,658 cancers. Nature 578:122–128. https://doi.org/10.1038/s41586-019-1907-7
doi: 10.1038/s41586-019-1907-7
Gong S, Li Q, Jeter CR, Fan Q, Tang DG, Liu B (2015) Regulation of NANOG in cancer cells. Mol Carcinog 54:679–687. https://doi.org/10.1002/mc.22340
doi: 10.1002/mc.22340
Gunnarsson EB, De S, Leder K, Foo J (2020) Understanding the role of phenotypic switching in cancer drug resistance. J Theor Biol 490:110162. https://doi.org/10.1016/j.jtbi.2020.110162
doi: 10.1016/j.jtbi.2020.110162
Jain P, Duddu AS, Jolly MK (2022) Stochastic population dynamics of cancer stemness and adaptive response to therapies. Essays Biochem 66:387–398. https://doi.org/10.1042/EBC20220038
doi: 10.1042/EBC20220038
Jeter CR, Yang T, Wang J, Chao H-P, Tang DG (2015) Concise review: NANOG in cancer stem cells and tumor development: an update and outstanding questions. Stem Cells 33:2381–2390. https://doi.org/10.1002/stem.2007
doi: 10.1002/stem.2007
Kalmar T, Lim C, Hayward P, Muñoz-Descalzo S, Nichols J, Garcia-Ojalvo J, Martinez AA (2009) Regulated fluctuations in nanog expression mediate cell fate decisions in embryonic stem cells. PLoS Biol 7:e1000149. https://doi.org/10.1371/journal.pbio.1000149
doi: 10.1371/journal.pbio.1000149
Kawamura N, Nimura K, Nagano H, Yamaguchi S, Nonomura N, Kaneda Y, Kawamura N, Nimura K, Nagano H, Yamaguchi S, Nonomura N, Kaneda Y (2015) CRISPR/Cas9-mediated gene knockout of NANOG and NANOGP8 decreases the malignant potential of prostate cancer cells. Oncotarget 6:22361–22374
Kim C, Gao R, Sei E, Brandt R, Hartman J, Hatschek T, Crosetto N, Foukakis T, Navin NE (2018) Chemoresistance evolution in triple-negative breast cancer delineated by single-cell sequencing. Cell 173:879-893.e13. https://doi.org/10.1016/j.cell.2018.03.041
doi: 10.1016/j.cell.2018.03.041
Kiyohara E, Tamai K, Katayama I, Kaneda Y (2012) The combination of chemotherapy with HVJ-E containing Rad51 siRNA elicited diverse anti-tumor effects and synergistically suppressed melanoma. Gene Ther 19:734–741. https://doi.org/10.1038/gt.2011.123
doi: 10.1038/gt.2011.123
Kreso A, O’Brien CA, van Galen P, Gan OI, Notta F, Brown AMK, Ng K, Ma J, Wienholds E, Dunant C, Pollett A, Gallinger S, McPherson J, Mullighan CG, Shibata D, Dick JE (2013) Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer. Science 339:543–548. https://doi.org/10.1126/science.1227670
doi: 10.1126/science.1227670
Kurooka M, Kaneda Y (2007) Inactivated Sendai virus particles eradicate tumors by inducing immune responses through blocking regulatory T cells. Cancer Res 67:227–236. https://doi.org/10.1158/0008-5472.CAN-06-1615
doi: 10.1158/0008-5472.CAN-06-1615
Lambert AW, Pattabiraman DR, Weinberg RA (2017) Emerging biological principles of metastasis. Cell 168:670–691. https://doi.org/10.1016/j.cell.2016.11.037
doi: 10.1016/j.cell.2016.11.037
Lan X, Jörg DJ, Cavalli FMG, Richards LM, Nguyen LV, Vanner RJ, Guilhamon P, Lee L, Kushida MM, Pellacani D, Park NI, Coutinho FJ, Whetstone H, Selvadurai HJ, Che C, Luu B, Carles A, Moksa M, Rastegar N, Head R, Dolma S, Prinos P, Cusimano MD, Das S, Bernstein M, Arrowsmith CH, Mungall AJ, Moore RA, Ma Y, Gallo M, Lupien M, Pugh TJ, Taylor MD, Hirst M, Eaves CJ, Simons BD, Dirks PB (2017) Fate mapping of human glioblastoma reveals an invariant stem cell hierarchy. Nature 549:227–232. https://doi.org/10.1038/nature23666
doi: 10.1038/nature23666
Lin J (1991) Divergence measures based on the Shannon entropy. IEEE Trans Inf Theory 37:145–151. https://doi.org/10.1109/18.61115
doi: 10.1109/18.61115
Lu R, Neff NF, Quake SR, Weissman IL (2011) Tracking single hematopoietic stem cells in vivo using high-throughput sequencing in conjunction with viral genetic barcoding. Nat Biotech 29:928–933. https://doi.org/10.1038/nbt.1977
doi: 10.1038/nbt.1977
Martin M (2011) Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet.journal 17:10–12. https://doi.org/10.14806/ej.17.1.200
doi: 10.14806/ej.17.1.200
Matsushima-Miyagi T, Hatano K, Nomura M, Li-Wen L, Nishikawa T, Saga K, Shimbo T, Kaneda Y (2012) TRAIL and Noxa are selectively upregulated in prostate cancer cells downstream of the RIG-I/MAVS signaling pathway by nonreplicating Sendai virus particles. Clin Cancer Res 18:6271–6283. https://doi.org/10.1158/1078-0432.CCR-12-1595
doi: 10.1158/1078-0432.CCR-12-1595
Merino D, Weber TS, Serrano A, Vaillant F, Liu K, Pal B, Stefano LD, Schreuder J, Lin D, Chen Y, Asselin-Labat ML, Schumacher TN, Cameron D, Smyth GK, Papenfuss AT, Lindeman GJ, Visvader JE, Naik SH (2019) Barcoding reveals complex clonal behavior in patient-derived xenografts of metastatic triple negative breast cancer. Nat Commun 10:766. https://doi.org/10.1038/s41467-019-08595-2
doi: 10.1038/s41467-019-08595-2
Nguyen LV, Cox CL, Eirew P, Knapp DJHF, Pellacani D, Kannan N, Carles A, Moksa M, Balani S, Shah S, Hirst M, Aparicio S, Eaves CJ (2014) DNA barcoding reveals diverse growth kinetics of human breast tumour subclones in serially passaged xenografts. Nat Commun 5:5871. https://doi.org/10.1038/ncomms6871
doi: 10.1038/ncomms6871
Pan YC, Nishikawa T, Chang CY, Tai JA, Kaneda Y (2021) CXCL2 combined with HVJ-E suppresses tumor growth and lung metastasis in breast cancer and enhances anti-PD-1 antibody therapy. Molecular Therapy - Oncolytics 20:175–186. https://doi.org/10.1016/j.omto.2020.12.011
doi: 10.1016/j.omto.2020.12.011
Perli SD, Cui CH, Lu TK (2016) Continuous genetic recording with self-targeting CRISPR-Cas in human cells. Science 353:aag0511–aag0511. https://doi.org/10.1126/science.aag0511
doi: 10.1126/science.aag0511
Prager BC, Xie Q, Bao S, Rich JN (2019) Cancer stem cells: the architects of the tumor ecosystem. Cell Stem Cell 24:41–53. https://doi.org/10.1016/j.stem.2018.12.009
doi: 10.1016/j.stem.2018.12.009
Quinn JJ, Jones MG, Okimoto RA, Nanjo S, Chan MM, Yosef N, Bivona TG, Weissman JS (2021) Single-cell lineages reveal the rates, routes, and drivers of metastasis in cancer xenografts. Science. https://doi.org/10.1126/science.abc1944
doi: 10.1126/science.abc1944
Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, Morrison SJ (2008) Efficient tumour formation by single human melanoma cells. Nature 456:593–598. https://doi.org/10.1038/nature07567
doi: 10.1038/nature07567
Saga K, Park J, Nimura K, Kawamura N, Ishibashi A, Nonomura N, Kaneda Y (2019) NANOG helps cancer cells escape NK cell attack by downregulating ICAM1 during tumorigenesis. J Exp Clin Cancer Res 38:416. https://doi.org/10.1186/s13046-019-1429-z
doi: 10.1186/s13046-019-1429-z
Salgia R, Kulkarni P (2018) The genetic/non-genetic duality of drug ‘resistance’ in cancer. Trends in Cancer 4:110–118. https://doi.org/10.1016/j.trecan.2018.01.001
doi: 10.1016/j.trecan.2018.01.001
Shaffer SM, Dunagin MC, Torborg SR, Torre EA, Emert B, Krepler C, Beqiri M, Sproesser K, Brafford PA, Xiao M, Eggan E, Anastopoulos IN, Vargas-Garcia CA, Singh A, Nathanson KL, Herlyn M, Raj A (2017) Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance. Nature 546:431–435. https://doi.org/10.1038/nature22794
doi: 10.1038/nature22794
Siebenthall KT, Miller CP, Vierstra JD, Mathieu J, Tretiakova M, Reynolds A, Sandstrom R, Rynes E, Haugen E, Johnson A, Nelson J, Bates D, Diegel M, Dunn D, Frerker M, Buckley M, Kaul R, Zheng Y, Himmelfarb J, Ruohola-Baker H, Akilesh S (2019) Integrated epigenomic profiling reveals endogenous retrovirus reactivation in renal cell carcinoma. EBioMedicine 41:427–442. https://doi.org/10.1016/j.ebiom.2019.01.063
doi: 10.1016/j.ebiom.2019.01.063
Smith T, Heger A, Sudbery I (2017) UMI-tools: modeling sequencing errors in Unique Molecular Identifiers to improve quantification accuracy. Genome Res 27:491–499. https://doi.org/10.1101/gr.209601.116
doi: 10.1101/gr.209601.116
Sun J, Ramos A, Chapman B, Johnnidis JB, Le L, Ho Y-J, Klein A, Hofmann O, Camargo FD (2014) Clonal dynamics of native haematopoiesis. Nature 514:322–327. https://doi.org/10.1038/nature13824
doi: 10.1038/nature13824
Turajlic S, Swanton C (2016) Metastasis as an evolutionary process. Science 352:169–175. https://doi.org/10.1126/science.aaf2784
doi: 10.1126/science.aaf2784
Turksen K (ed) (2016) Stem cell heterogeneity: methods and protocols, methods in molecular biology. Springer, New York
Vendramin R, Litchfield K, Swanton C (2021) Cancer evolution: darwin and beyond. EMBO J 40:e108389. https://doi.org/10.15252/embj.2021108389
doi: 10.15252/embj.2021108389
Wagenblast E, Soto M, Gutiérrez-Ángel S, Hartl CA, Gable AL, Maceli AR, Erard N, Williams AM, Kim SY, Dickopf S, Harrell JC, Smith AD, Perou CM, Wilkinson JE, Hannon GJ, Knott SRV (2015) A model of breast cancer heterogeneity reveals vascular mimicry as a driver of metastasis. Nature. https://doi.org/10.1038/nature14403
doi: 10.1038/nature14403
Zhang S, Xiong X, Sun Y (2020) Functional characterization of SOX2 as an anticancer target. Sig Transduct Target Ther 5:1–17. https://doi.org/10.1038/s41392-020-00242-3
doi: 10.1038/s41392-020-00242-3